NCT02441686View on ClinicalTrials.gov

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2021

Study Completion Date

October 31, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib

DRUG

Lenalidomide

DRUG

Dexamethasone

PROCEDURE

Stem Cell Mobilization

PROCEDURE

Autologous Stem Cell Transplant

Trial Locations (8)

55407

Virgina Piper Cancer Institute, Minneapolis

55433

Virginia Piper Cancer Institute, Coon Rapids

80218

Colorado Blood Cancer Institute, Denver

04412

Eastern Maine Medical Center, Brewer

02114

Massachusetts General Hosptial, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

07962

Hematology Oncology of Northern New Jersey, Morristown

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

Celgene

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER